15-Year Cumulative Savings
$2.1T
vs. maintaining 40% obesity rate
Annual Savings by Year
$573B
$287B
$0
There are several industries that will certainly be affected by the HOTs disruption, some more severely than others. Some of the industries that will be the most severely disrupted include:
The traditional dieting and weight loss industry
This industry is already effectively disrupted. The $75 billion sector, built on the premise that weight loss is difficult and requires ongoing behavioral and product support, cannot compete with drugs that simply work. Key players have clearly struggled, like WeightWatchers, which filed for bankruptcy in April 2025 before largely centering itself around GLP-1s, and Jenny Craig, which filed for bankruptcy and went out of business in 2023. The fitness industry faces a similar reckoning as gyms and programs built around weight loss as a primary motivator will need to pivot toward performance, capability, and general wellbeing, or risk the same fate as the diet industry incumbents that failed to adapt.
Healthcare industry
Healthcare industries serving obesity-linked conditions face enormous demand collapse. Over $2.3 trillion of US healthcare spending annually is tied to conditions driven by metabolic risk such as type 2 diabetes ($305B), cardiovascular disease ($415B), osteoarthritis ($140B), sleep apnea ($95B), Alzheimer's and dementias ($380B), and more. Hospitals and healthcare systems built around managing the chronic downstream consequences of obesity face a structural decline in their core business. This is particularly acute for systems organized around expensive, high-margin interventional procedures. Bariatric surgery, which once performed over 275,000 procedures annually in the US, faces obsolescence as multi-agonist drugs approach comparable weight loss without surgical risk, hospitalization, or irreversibility.
The food and beverage industry
GLP-1 users report disproportionate reduction in junk food and indulgence consumption precisely because these drugs modulate the dopamine reward circuitry that drives impulsive eating. A plausible one-third decline in junk food demand translates into $300 billion in annual US revenue loss. The hardest-hit segments will be the highest-margin ones, like soft drinks, desserts, alcoholic beverages, and fast food.
Potentially addictive product industries
Alcohol, tobacco, gambling, and illicit drugs, collectively over $800 billion in US revenues, all face structural decline as the dopamine-modulating effects of HOTs reduce the hedonic value and craving intensity associated with these products and behaviors. The tobacco industry and the illicit drug supply chain face especially severe long-term demand destruction.
Agriculture
Overall food demand declines translate directly into agricultural demand declines. Grains (especially corn, much of which goes into high-fructose corn syrup), sugar, and dairy face the largest impacts. The corn farming and high-fructose corn syrup industry is particularly exposed.
Industries facing growth include HOT developers and manufacturers, telehealth platforms specializing in HOT management, sports medicine and performance optimization services, outdoor recreation and sporting goods (from a leaner, more active population), activewear and athleisure, and cosmetic surgery (for addressing skin changes after significant weight loss).
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.